DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design

* stage 3b: eGFR = 30 to < 45 mL/min/1.73m² ; stage 4: eGFR = 15 to < 30 mL ; stage 5: eGFR<15 mL or dialysis-dependent

• GLE/PIB: 100/40 mg 3 tablets QD, administered regardless of timing of dialysis (hemo- or peritoneal)

Primary endpoint

• SVR₁₂ (HCV < LLOQ)

Baseline characteristics

Primary Endpoint (SVR₁₂)

* 1 patient had missing data and 2 patients discontinued treatment
** 1 patient with NS5A Y93H RAS achieved SVR₁₂

Adverse events and laboratory abnormalities, %

* No AE related to treatment
No death observed

Renal function

• Of the 24 patients with CKD stage 3b or 4 and with available results, eGFR remained unchanged from screening to end of treatment and post-treatment week 4: 27.1 ± 9.2 vs 26.4 ± 9.8 vs 27.4 ± 11.6 mL/min/1.73m²
• CKD stage remained unchanged in 22/24 patients with end of treatment results and declined in 2/24 from screening to end of treatment

Summary

• GLE/PIB is highly efficacious in patients with chronic kidney disease stage 3b to 5 with the label recommended treatment durations based on genotype, cirrhosis status and prior treatment experience
  Treatment was well-tolerated
• Overall, renal function remained unchanged after treatment in pre-dialysis patients assessed